Overview

A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

Status:
Not yet recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
The main aim is to see how leuprolide works to treat central precocious puberty in children. Participants will receive an injection of leuprorelin acetate depot 11.25 mg every 12 weeks during 6 months and will visit their study clinic 6 times to complete some assessments.
Phase:
Phase 4
Details
Lead Sponsor:
Takeda
Treatments:
Leuprolide